Levetiracetam Tablets USP, 250 mg UD 100 Tablets (10x10) boxes, Rx Only, Distributed By: McKesson...
FDA Drug Recall #D-0630-2021 — Class III — May 26, 2021
Recall Summary
| Recall Number | D-0630-2021 |
| Classification | Class III — Low risk |
| Date Initiated | May 26, 2021 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | McKesson Corporation dba McKesson Drug Company |
| Location | Memphis, TN |
| Product Type | Drugs |
| Quantity | 210 cartons |
Product Description
Levetiracetam Tablets USP, 250 mg UD 100 Tablets (10x10) boxes, Rx Only, Distributed By: McKesson Corporation 4971 Southridge Blvd., Suite 101 Memphis, TN 38141 Manufactured by: Aurobindo Pharma Limited Hyderabad-500 090, India NDC 63739-795-10
Reason for Recall
Labeling; Wrong Barcode; error in the machine-readable barcode which could result in some units being read as Naproxen Tablets 500 mg. Product is labeled correctly as Levetiracetam
Distribution Pattern
Nationwide in the US
Lot / Code Information
Lot: 0000124916 Exp. 09/30/2022
Other Recalls from McKesson Corporation dba McKesson Dru...
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0848-2022 | Class II | Lidocaine Hydrochloride Topical Solution USP 4%... | Apr 21, 2022 |
| D-0851-2022 | Class II | Erythromycin Topical Gel USP, 2%, Net Wt 60 g t... | Apr 21, 2022 |
| D-0847-2022 | Class II | Halobetasol Propionate Ointment 0.05% Net Wt., ... | Apr 21, 2022 |
| D-0849-2022 | Class II | Lidocaine Prilocaine Cream USP, 2.5%/2.5% Net W... | Apr 21, 2022 |
| D-0850-2022 | Class II | Betamethasone Dipropionate Ointment USP, 0.05%*... | Apr 21, 2022 |
Frequently Asked Questions
Stop using the medication immediately and contact your pharmacist. A mislabeling recall can range from a minor technical error (wrong font size) to a serious mix-up where one drug is inside another drug's packaging. If you received a medication that looks or acts differently than expected, or if you experienced unexpected effects, tell your doctor immediately. The pharmacist can verify whether your specific lot is affected and provide a replacement. Report any adverse effects experienced to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.